| Literature DB >> 31485543 |
M C López1, A Vila1, J Rodón2, X Roura1.
Abstract
Leptospira is a widespread zoonosis that has been linked to transmission between dogs and humans. The main purposes were to determine the seroprevalence of anti-Leptospira serum antibody and to identify the most common serovars in dogs in Spain. This is a cross-sectional study with 1,310 records of canine Leptospira testing data from Spain since 2015 to 2017. Inclusion criteria were individual cases with MAT test results for 8 serovars (Bratislava, Icterohaemorrhagiae, Australis, Pomona, Grippotyphosa, Autumnalis, Canicola and Saxkoebing) and to have the zip code data. Three hundred and thirty-eight samples (25.8%; 95%CI 23.6-28.4) were seropositive (≥1:100). According to geographic areas, North had the highest seroprevalence (38.0%; 95%CI 28.9-47.1) followed by South (29.4%; 95%CI 20.1-38.8), Center (28.6%; 95%CI 24.3-33.0), Mediterranean (22.3%; 95%CI 19.1-25.6) and Northwest (22.2%; 95%CI 7.9-36.4). Seropositivity (MAT ≥1:100) was most common to serovars Icterohaemorrhagiae (19.4%; 95%CI 17.2-21.5) and Bratislava (8.5%; 95%CI 7.0-10.0), followed by Grippotyphosa (7.2%; 95%CI 5.8-8.6), Australis (6.4%; 95%CI 5.0-7.7), Autumnalis (5.0%; 95%CI 3.8-6.2), Pomona (4.5%; 95%CI 3.3-5.6), Canicola (3.4%; 95%CI 2.4-4.4) and Saxkoebing (0.8%; 95%CI 0.3-1.3). An association was found between positivity (MAT ≥1:100) and males (P = 0.003) and dogs that were 6 years old or older were at higher risk of exposure (P = 0.001; OR 4.61; 95%CI 1.86-11.43). This study has shown that dogs in Spain are commonly exposed to Leptospira infection and points out the necessity to control the prevalence of this severe widespread zoonosis in dogs and humans.Entities:
Keywords: Canine leptospirosis; Epidemiology; Europe; Infectious disease; Internal medicine; Leptospirosis; MAT; Microbiology; Public health; Systems biology; Veterinary medicine; Zoology
Year: 2019 PMID: 31485543 PMCID: PMC6717157 DOI: 10.1016/j.heliyon.2019.e02373
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Panel of 8 Leptospira spp. used as live antigens for microscopic agglutination testing.
| Genomospecies | Serogroup | Serovar |
|---|---|---|
| Australis | Bratislava | |
| Australis | Australis | |
| Autumnalis | Autumnalis | |
| Icterohaemorrhagiae | Icterohaemorrhagiae | |
| Pomona | Pomona | |
| Sejroe | Saxkoebing | |
| Grippothyphosa | Grippothyposa |
Fig. 1The geographical distribution of positive dogs tested for serum antibodies Leptospira spp. with MAT (n = 338). Geocoding was performed based on the zip code. Geographic areas: Mediterranean (M), Northwest (NW), North (N), Center (C), and South (S).
Number of individuals (n), relative prevalence and 95% confidence interval (CI) per Leptospira serovar for all dogs (n = 1310). Tested serovars: Bratislava (BRA), Icterohaemorrhagie (ICT), Australis (AUS), Pomona (POM), Grippotyphosa (GRI), Autumnalis (AUT), Canicola (CAN) and Saxkoebing (SAX).
| MAT Titer | All Serovars | BRA | ICT | AUS | POM | GRI | AUT | CAN | SAX | |
|---|---|---|---|---|---|---|---|---|---|---|
| ≥1:100 | n | 338 | 111 | 254 | 84 | 59 | 94 | 66 | 44 | 11 |
| % | 25.8 | 8.5 | 19.4 | 6.4 | 4.5 | 7.2 | 5.0 | 3.4 | 0.8 | |
| CI | 23.6–28.4 | 7.0–10.0 | 17.2–21.5 | 5.0–7.7 | 3.3–5.6 | 5.8–8.6 | 3.8–6.2 | 2.4–4.4 | 0.3–1.3 | |
| ≥1:200 | n | 223 | 84 | 155 | 56 | 43 | 67 | 41 | 21 | 9 |
| % | 17.0 | 6.4 | 11.8 | 4.3 | 3.3 | 5.1 | 3.1 | 1.6 | 0.7 | |
| CI | 15.0–19.1 | 5.1–7.7 | 10.1–13.6 | 3.2–5.4 | 2.3–4.2 | 3.9–6.3 | 2.2–4.1 | 0.9–2.3 | 0.2–1.1 | |
| ≥1:400 | n | 122 | 54 | 72 | 29 | 30 | 35 | 25 | 13 | 8 |
| % | 9.3 | 4.1 | 5.5 | 2.2 | 2.3 | 2.7 | 1.9 | 1.0 | 0.6 | |
| CI | 7.8–10.9 | 3.0–5.2 | 4.3–6.7 | 1.4–3.0 | 1.5–3.1 | 1.8–3.5 | 1.2–2.6 | 0.4–1.5 | 0.2–1.0 | |
| ≥1:800 | n | 77 | 35 | 39 | 14 | 16 | 23 | 15 | 3 | 4 |
| % | 5.9 | 2.7 | 3.0 | 1.1 | 1.2 | 1.8 | 1.1 | 0.2 | 0.3 | |
| CI | 4.6–7.2 | 1.8–3.5 | 2.1–3.9 | 0.5–1.6 | 0.6–1.8 | 1.0–2.5 | 0.5–1.7 | 0.0–0.5 | 0.0–0.6 | |
| ≥1:1600 | n | 44 | 11 | 21 | 7 | 6 | 16 | 5 | 1 | 2 |
| % | 3.4 | 0.8 | 1.6 | 0.5 | 0.5 | 1.2 | 0.4 | 0.1 | 0.2 | |
| CI | 2.4–4.4 | 0.3–1.3 | 0.9–2.3 | 0.1–0.9 | 0.1–0.8 | 1.6–1.8 | 0.1–0.7 | 0.0–0.2 | 0.0–0.4 | |
| ≥1:3200 | n | 19 | 2 | 8 | 2 | 1 | 11 | - | 1 | - |
| % | 1.5 | 0.2 | 0.6 | 0.2 | 0.1 | 0.8 | - | 0.1 | - | |
| CI | 0.8–2.1 | 0.0–0.4 | 0.2–1.0 | 0.0–0.4 | 0.0–0.2 | 0.3–1.3 | - | 0.0–0.2 | - | |
| ≥1:6400 | n | 11 | 2 | 4 | - | 1 | 5 | - | 1 | - |
| % | 0.8 | 0.2 | 0.3 | - | 0.1 | 0.4 | - | 0.1 | - | |
| CI | 0.3–1.3 | 0.0–0.4 | 0.0–0.6 | - | 0.0–0.2 | 0.1–0.7 | - | 0.0–0.2 | - | |
Number of individuals (n), relative prevalence and 95% confidence interval (CI) per Leptospira serogroup for all dogs (n = 1310). Tested serogroups: Australis (AUS), Icterohaemorrhagie (ICT), Pomona (POM), Grippotyphosa (GRI), Autumnalis (AUT), Canicola (CAN) and Sejroe (SAX).
| MAT Titer | All Serogroups | AUS | ICT | POM | GRI | AUT | CAN | SEJ | |
|---|---|---|---|---|---|---|---|---|---|
| ≥1:100 | n | 338 | 117 | 254 | 59 | 94 | 66 | 44 | 11 |
| % | 25.8 | 8.9 | 19.4 | 4.5 | 7.2 | 5.0 | 3.4 | 0.8 | |
| CI | 23.6–28.4 | 7.4–10.5 | 17.2–21.5 | 3.3–5.6 | 5.8–8.6 | 3.8–6.2 | 2.4–4.4 | 0.3–1.3 | |
| ≥1:200 | n | 223 | 89 | 155 | 43 | 67 | 41 | 21 | 9 |
| % | 17.0 | 6.8 | 11.8 | 3.3 | 5.1 | 3.1 | 1.6 | 0.7 | |
| CI | 15.0–19.1 | 5.4–8.2 | 10.1–13.6 | 2.3–4.2 | 3.9–6.3 | 2.2–4.1 | 0.9–2.3 | 0.2–1.1 | |
| ≥1:400 | n | 122 | 57 | 72 | 30 | 35 | 25 | 13 | 8 |
| % | 9.3 | 4.4 | 5.5 | 2.3 | 2.7 | 1.9 | 1.0 | 0.6 | |
| CI | 7.8–10.9 | 3.3–5.5 | 4.3–6.7 | 1.5–3.1 | 1.8–3.5 | 1.2–2.6 | 0.4–1.5 | 0.2–1.0 | |
| ≥1:800 | n | 77 | 37 | 39 | 16 | 23 | 15 | 3 | 4 |
| % | 5.9 | 2.8 | 3.0 | 1.2 | 1.8 | 1.1 | 0.2 | 0.3 | |
| CI | 4.6–7.2 | 1.9–3.7 | 2.1–3.9 | 0.6–1.8 | 1.0–2.5 | 0.5–1.7 | 0.0–0.5 | 0.0–0.6 | |
| ≥1:1600 | n | 44 | 15 | 21 | 6 | 16 | 5 | 1 | 2 |
| % | 3.4 | 1.1 | 1.6 | 0.5 | 1.2 | 0.4 | 0.1 | 0.2 | |
| CI | 2.4–4.4 | 0.6–1.7 | 0.9–2.3 | 0.1–0.8 | 1.6–1.8 | 0.1–0.7 | 0.0–0.2 | 0.0–0.4 | |
| ≥1:3200 | n | 19 | 3 | 8 | 1 | 11 | - | 1 | - |
| % | 1.5 | 0.2 | 0.6 | 0.1 | 0.8 | - | 0.1 | - | |
| CI | 0.8–2.1 | 0.0–0.5 | 0.2–1.0 | 0.0–0.2 | 0.3–1.3 | - | 0.0–0.2 | - | |
| ≥1:6400 | n | 11 | 2 | 4 | 1 | 5 | - | 1 | - |
| % | 0.8 | 0.2 | 0.3 | 0.1 | 0.4 | - | 0.1 | - | |
| CI | 0.3–1.3 | 0.0–0.4 | 0.0–0.6 | 0.0–0.2 | 0.1–0.7 | - | 0.0–0.2 | - | |
Number of individuals positive against one, two or more serovars at a MAT Titer of ≥100 and ≥400.
| Nº seropositive serovars | MAT ≥1:100 n (%) | MAT ≥1:400 n (%) |
|---|---|---|
| 1 | 183 (54.2) | 55 (45.0) |
| 2 | 54 (16.0) | 25 (20.5) |
| 3 | 32 (9.5) | 20 (16.4) |
| 4 | 27 (8.0) | 11 (9.0) |
| 5 | 24 (7.1) | 9 (7.4) |
| 6 | 14 (4.1) | 2 (1.6) |
| 7 | 4 (1.2) | 0 (0) |
| 8 | 0 (0) | 0 (0) |
Multivariable analysis of the association between sex, age, season and region with positive against any serovar at MAT titers ≥100, ≥400 and Icterohaemorrhagiae (ICT) serovar for titer ≥100.
| Covariate | Levels | Cut-Off | Odds ratio | 95%CI | p-value |
|---|---|---|---|---|---|
| Sex | Female | Ref. | |||
| Male | ≥1:100 | 2.16 | 0.90–5.19 | 0.086 | |
| ≥1:400 | 4.03 | 0.44–37.14 | 0.218 | ||
| ICT | 1.53 | 0.60–3.87 | 0.367 | ||
| Age | <6y | Ref | |||
| ≥6y | ≥1:100 | 4.61 | 1.86–11.43 | 0.001* | |
| ≥1:400 | 2.73 | 0.41–18.17 | 0.300 | ||
| ICT | 3.73 | 1.42–9.77 | 0.007* | ||
| Season | W | Ref. | |||
| SP | ≥1:100 | 0.72 | 0.21–2.44 | 0.602 | |
| ≥1:400 | 1.37 | 0.09–20.15 | 0.818 | ||
| ICT | 0.62 | 0.18–2.22 | 0.467 | ||
| SU | ≥1:100 | 0.50 | 0.14–1.83 | 0.295 | |
| ≥1:400 | 1.21 | 0.09–16.31 | 0.890 | ||
| ICT | 0.73 | 0.20–2.67 | 0.634 | ||
| A | ≥1:100 | 0.52 | 0.15–1.87 | 0.319 | |
| ≥1:400 | 0.87 | 0.04–37.14 | 0.926 | ||
| ICT | 0.36 | 0.09–1.48 | 0.160 | ||
| Region | S | Ref. | |||
| M | ≥1:100 | 0.33 | 0.08–1.37 | 0.126 | |
| ≥1:400 | 0.15 | 0.01–2.70 | 0.195 | ||
| ICT | 0.40 | 0.08–1.86 | 0.242 | ||
| NW | ≥1:100 | - | - | - | |
| ≥1:400 | - | - | - | ||
| ICT | - | - | - | ||
| N | ≥1:100 | 1.27 | 0.18–8.93 | 0.813 | |
| ≥1:400 | 2.04 | 0.09–46.21 | 0.654 | ||
| ICT | 0.90 | 0.10–7.83 | 0.242 | ||
| C | ≥1:100 | 0.55 | 1.86–11.43 | 0.423 | |
| ≥1:400 | 0.68 | 0.06–8.11 | 0.760 | ||
| ICT | 0.67 | 0.14–3.21 | 0.618 |
*Statistically significant (p < 0.05).
Analysis of association (χ2) between season, sex, region or age with positive microscopic agglutination test against any of the tested serovars at MAT cut-offs ≥1:100 (ALL 100) and ≥1:400 (ALL 400); and against each serovar at MAT cut-off ≥1:100 for serovars Bratislava (BRA), Icterohamorrhagiae (ICT), Australis (AUS), Gripothypposa (GRI), Autumnalis (AUT), Canicola (CAN) and Saxkoebing (SAX).
| Variable | ALL100 | ALL400 | BRA100 | ICT100 | AUS100 | POM100 | GRI100 | AUT100 | CAN100 | SAX100 |
|---|---|---|---|---|---|---|---|---|---|---|
| SEASON | 0.187 | 0.060 | 0.232 | 0.254 | 0.512 | 0.149 | 0.039 | 0.09 | 0.373 | 0.426 |
| SEX | 0.003 | 0.015 | 0.015 | 0.023 | 0.072 | 0.407 | 1.000 | 0.023 | 0.085 | 1.000 |
| REGION | 0.001 | 0.042 | 0.373 | 0.301 | 0.402 | 0.208 | 0.003 | 0.257 | 0.241 | - |
| AGE | 0.001 | 0.735 | 0.729 | 0.000 | 1.000 | 0.689 | 0.456 | 1.000 | 0.663 | - |
Statistically significant (p < 0.05).
Fisher's test used.
Number of titers (n) and relative prevalence for MAT cut-off ≥100 divided by geographic areas and serovar. Serovars tested: Bratislava (BRA), Icterohaemorrhagie (ICT), Australis (AUS), Pomona (POM), Grippotyphosa (GRI), Autumnalis (AUT), Canicola (CAN), and Saxkoebing (SAX).
| Region | All Serovars | BRA | ICT | AUS | POM | GRI | AUT | CAN | SAX | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mediterranean | n | 147 | 48 | 115 | 40 | 20 | 28 | 27 | 21 | 3 |
| % | 22.3 | 7.4 | 17.9 | 6.2 | 3.1 | 4.3 | 4.2 | 3.2 | 0.5 | |
| CI | 19.1–25.6 | 5.4–9.5 | 14.9–20.8 | 4.3–8.1 | 1.7–4.4 | 2.7–5.9 | 2.6–5.7 | 1.9–4.6 | 0.0–1.0 | |
| Northwest | n | 8 | 3 | 4 | 2 | 2 | 2 | 2 | 1 | 0 |
| % | 22.2 | 8.3 | 11.1 | 5.6 | 5.6 | 5.6 | 5.6 | 2.8 | - | |
| CI | 7.9–36.4 | 0.0–17.8 | 0.3–21.9 | 0.0–13.4 | 0.0–13.4 | 0.0–13.4 | 0.0–13.4 | 0.0–8.4 | - | |
| North | n | 44 | 13 | 25 | 12 | 7 | 10 | 8 | 1 | 6 |
| % | 38.0 | 11.5 | 22.1 | 10.6 | 6.2 | 8.8 | 7.1 | 0.8 | 5.3 | |
| CI | 28.9–47.1 | 5.5–17.5 | 14.3–29.9 | 4.8–16.4 | 1.7–10.7 | 3.5–14.2 | 2.3–11.9 | 0.0–2.6 | 1.1–9.5 | |
| Center | n | 125 | 36 | 88 | 23 | 25 | 47 | 23 | 18 | 1 |
| % | 28.6 | 8.5 | 20.8 | 5.4 | 5.9 | 11.1 | 5.4 | 4.2 | 0.2 | |
| CI | 24.3–33.0 | 5.8–11.2 | 17.0–24.7 | 3.3–7.6 | 3.3–7.6 | 8.1–14.1 | 3.3–7.6 | 2.3–6.2 | 0.0–0.7 | |
| South | n | 27 | 11 | 22 | 7 | 5 | 7 | 6 | 3 | 1 |
| % | 29.4 | 11.5 | 23.2 | 7.4 | 7.4 | 7.4 | 6.3 | 3.2 | 1.0 | |
| CI | 20.1–38.8 | 5.0–18.1 | 14.5–31.8 | 2.0–12.7 | 2.0–12.7 | 2.0–12.7 | 1.3–11.3 | 0.0–6.7 | 0.0–3.1 | |